C.R. Bard, Inc.  

(Public, NYSE:BCR)   Watch this stock  
Find more results for BCR
111.80
+1.17 (1.06%)
After Hours: 111.80 0.00 (0.00%)
Jun 18, 4:29PM EDT  
NYSE real-time data - Disclaimer
Currency in USD
Range 110.78 - 112.09
52 week 93.69 - 112.28
Open 111.05
Vol / Avg. 479,611.00/574,704.00
Mkt cap 9.00B
P/E 19.85
Div/yield 0.21/0.75
EPS 5.63
Shares 80.48M
Beta 0.39
Inst. own 86%
Jul 26, 2013
Q2 2013 C. R. Bard, Inc. Earnings Release Add to calendar
Jun 3, 2013
C. R. Bard, Inc. Analyst Meeting - Webcast
Apr 23, 2013
Q1 2013 C. R. Bard, Inc. Earnings Conference Call - Webcast
Apr 17, 2013
C. R. Bard, Inc. Annual Shareholder Meeting
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '13) 2012
Net profit margin 12.25% 17.92%
Operating margin 17.24% 24.76%
EBITD margin - 31.93%
Return on average assets 8.84% 13.12%
Return on average equity 18.67% 28.14%
Employees 12,200 -
Carbon Disclosure Rating - -

Address

730 Central Avenue
MURRAY HILL, NJ 07974
United States - Map
+1-908-2778000 (Phone)
+1-908-2778412 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Discussion Group - Google Finance

Description

C. R. Bard, Inc. (Bard) is engaged in the design, manufacture, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. As of December 31, 2011, the Company sold a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis. The Company participates in the markets for vascular, urology, oncology and surgical specialty products. Bard also has a product group of other products. Through subsidiaries and a joint venture, Bard markets its products to customers in over 100 countries outside the United States. The Company�s principal international markets were in Europe and Japan as of December 31, 2011. On November 10, 2011, Bard acquired Medivance, Inc. On December 16, 2011, the Company acquired Lutonix, Inc.

Officers and directors

Timothy M. Ring Chairman of the Board, Chief Executive Officer
Age: 55
Bio & Compensation  - Reuters
John H. Weiland President, Chief Operating Officer, Director
Age: 57
Bio & Compensation  - Reuters
Christopher S. Holland Chief Financial Officer, Senior Vice President
Age: 46
Bio & Compensation  - Reuters
John A. DeFord Ph.D. Senior Vice President - Science, Technology and Clinical Affairs
Age: 51
Bio & Compensation  - Reuters
Gary D. Dolch Senior Vice President - Quality, Regulatory and Medical Affairs
Age: 65
Bio & Compensation  - Reuters
Jean F. Holloway Vice President, General Counsel, Secretary
Age: 56
Bio & Compensation  - Reuters
Frank Lupisella Jr. Vice President, Controller
Age: 52
Bio & Compensation  - Reuters
Bronwen K. Kelly Vice President - Human Resources
Age: 60
Bio & Compensation  - Reuters
Sharon M. Alterio Group Vice President
Age: 50
Bio & Compensation  - Reuters
Jim C. Beasley Group Vice President
Age: 49
Bio & Compensation  - Reuters